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Abstract
Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of Adult T cell Leukemia (ATL) and the neurological
disorder HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although the majority of HTLV-1–infected
individuals remain asymptomatic carriers (AC) during their lifetime, 2–5% will develop either ATL or HAM/TSP, but never
both. To better understand the gene expression changes in HTLV-1-associated diseases, we examined the mRNA profiles of
CD4+ T cells isolated from 7 ATL, 12 HAM/TSP, 11 AC and 8 non-infected controls. Using genomic approaches followed by
bioinformatic analysis, we identified gene expression pattern characteristic of HTLV-1 infected individuals and particular
disease states. Of particular interest, the suppressor of cytokine signaling 1—SOCS1—was upregulated in HAM/TSP and AC
patients but not in ATL. Moreover, SOCS1 was positively correlated with the expression of HTLV-1 mRNA in HAM/TSP
patient samples. In primary PBMCs transfected with a HTLV-1 proviral clone and in HTLV-1-transformed MT-2 cells, HTLV-1
replication correlated with induction of SOCS1 and inhibition of IFN-a/b and IFN-stimulated gene expression. Targeting
SOCS1 with siRNA restored type I IFN production and reduced HTLV-1 replication in MT-2 cells. Conversely, exogenous
expression of SOCS1 resulted in enhanced HTLV-1 mRNA synthesis. In addition to inhibiting signaling downstream of the
IFN receptor, SOCS1 inhibited IFN-b production by targeting IRF3 for ubiquitination and proteasomal degradation. These
observations identify a novel SOCS1 driven mechanism of evasion of the type I IFN antiviral response against HTLV-1.
Citation: Olie `re S, Hernandez E, Le ´zin A, Arguello M, Douville R, et al. (2010) HTLV-1 Evades Type I Interferon Antiviral Signaling by Inducing the Suppressor of
Cytokine Signaling 1 (SOCS1). PLoS Pathog 6(11): e1001177. doi:10.1371/journal.ppat.1001177
Editor: Susan R. Ross, University of Pennsylvania School of Medicine, United States of America
Received March 12, 2010; Accepted October 1, 2010; Published November 4, 2010
Copyright:  2010 Olie `re et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by grants from the National Cancer Institute (http://www.cancer.gov), the Canadian Cancer Society (http://www.cancer.
ca), the Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca), the Canadian Foundation for AIDS Research (CANFAR, http://www.canfar.com), and
Genome Quebec (http://www.genomequebec.com). SO and TLAN were supported by FRSQ (http://www.frsq.gouv.qc.ca) and JH is a recipient of a CIHR Senior
Investigator award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: john.hiscott@mcgill.ca
¤ Current address: Vaccine and Gene Therapy Institute – Florida, Port St. Lucie, Florida, United States of America
Introduction
Infection with the Human T cell Leukemia Virus type I
(HTLV-I) can result in a number of disorders, including the
aggressive T cell malignancy Adult T cell Leukemia (ATL) and the
chronic, progressive neurologic disorder termed HTLV-1-associ-
ated myelopathy/tropical spastic paraparesis (HAM/TSP) [1,2,3].
In endemic areas including Southern Japan, the Caribbean basin,
Western Africa and Central/South America - where infection
rates range from 2 to 30%- these diseases are major causes of
mortality and morbidity [4]. The majority of HTLV-1–infected
individuals remain asymptomatic (AC) during their lifetime and
only ,2–5% of AC will develop either ATL or HAM/TSP [5,6].
Although the factors determining progression from AC to ATL or
HAM/TSP remain unknown, it is well established that the risk of
ATL vs. HAM/TSP development varies dramatically with the
geographical distribution of HTLV-1-infected populations.
Clinically, acute ATL is characterized by abnormally elevated T
cell counts, accompanied by readily observed ‘flower cells’ – multi-
lobed, leukemic cells with highly condensed chromatin - hypercal-
cemia, prominent skin lesions, hepatosplenomegaly and suffer from
serious bacterial, viral, fungal and protozoan infections. Most
patients present at this final acute stage, often unaware of their
HTLV-1 positive status and given a poor prognosis, with a survival
estimate of 6–10 months [7]. Transformation of CD4+ T
lymphocytes by HTLV-1 and the development of ATL leukemo-
genesis generally occur in two stages [8,9]. After infection with the
blood borne pathogen, HTLV-1 induces IL-2-dependent, CD4+ T
cell proliferation, that over a period of decades in vivo, progresses
with the emergence of an IL-2-independent malignant clone that
has accumulated multiple secondary genetic changes in growth
regulatoryand tumorsuppressorgenes[9,10].HTLV-1encodesthe
40-kDa nuclear oncoprotein Tax that promotes cellular transfor-
mation through dysregulation of mitotic checkpoints, activation of
cellular signaling pathways and inactivation of tumor suppressors
(reviewed in [11,12]).
HAM/TSP is a systemic immune-mediated inflammatory
disease characterized by demyelination of motor neurons in the
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HAM/TSP attacks in the prime of life (median age of onset: 35
years) and is associated with a clinical history that includes
neurological symptoms in 80% of cases – gradual onset of leg
weakness, paresthesis, and impairment of urinaryor bowel function.
Central nervous system (CNS) white matter lesions of the spinal
cord harbor activated CD4
+ and CD8
+ T cells during early stages of
disease, with a predominance of CD8
+ T cells later in disease.
HTLV-1 viral RNA has been found associated with CD4
+ T cells
and astrocytes in CNS lesions, suggesting that virus-infected cells
migrate through the blood-brain barrier and infect CNS resident
cells [14,15]. While the mechanisms resulting in HAM/TSP
development remain unresolved, it has been suggested that Tax
expression in CNS cells triggers a strong virus-specific CD8
+ (as well
as CD4
+) T cell response leading to inflammation, myelin loss, and
axonal damage [16,17]. Elevated levels of proinflammatory
cytokines (IL-6, IFN-c, IL-15, IL-1b, TNF-a and IL-12) have been
detected in the serum and cerebrospinal fluid (CSF) of patients with
HAM/TSP, corroborating the link between HAM/STP develop-
ment and dysregulated inflammation [18,19].
It is widely accepted that type I interferon (IFN-a/b) has a
negative impact on HIV-1 replication [20,21], and although few
reports have documented the IFN antiviral effects during HTLV-1
infection, type I IFN constitutes a potent anti-retroviral mechanism
that affects HTLV-1 replication [22,23]. In return, HTLV-1
infection of pDCs results in impaired IFN-a production, and
correlates with elevated HTLV-1 proviral load in infected
individuals [24]. Central to the establishment of an antiviral state
is the activation of diverse IFN-stimulated genes (ISGs) which
restrict viral replication [25]. Interferonregulatoryfactors IRF3 and
IRF7 play essential roles in the early phase of IFN gene activation
[26]. IRF3 is constitutively expressed and is activated by C-terminal
phosphorylation by IKKe and TBK1, which promotes transactiva-
tion of downstream genes such as IFN-b and IFN-a [27,28]. In
contrast, IRF7 protein is synthesized de novo upon IFN stimulation
and contributes to the amplification of the IFN response, via
expression of multiple IFN-a subtypes [29]. IRF-driven IFN
secretion acts in a paracrine fashion to induce the expression of
hundreds of genes through engagement of the IFN receptors and
activation of the JAK/STAT signaling pathway, which leads to the
development of an antiviral state (reviewed in [30,31]).
IFN-induced JAK/STAT signaling is negatively regulated at
different levels by several cellular factors to control the extent of the
antiviral response and limit tissue damage [32,33]. Suppressor of
cytokine signaling 1 (SOCS1) belongs to the SOCS protein family
and is induced after virus infection [34]. SOCS1 suppresses IFN
signaling by direct binding to phosphorylated type I IFN receptor
and active JAK kinase, abrogating phosphorylation of STAT1 [35].
Through its SOCS-Box domain, SOCS1 targets various proteins
such as JAK, MAL, p65, Steel, Vav for proteasomal degradation
[36,37,38]. The SOCS-Box serves as a recruiting platform for the
formationofaE3ligasecomplexcomposedofelongin B/C-Cullin2
and Rbx2 [39,40]. Thus, SOCS1 initiates and orchestrates the
events leading to proteasomal degradation of target proteins [34].
Recently, virus-induced upregulation of SOCS1 protein has
emerged as a novel mechanism employed by several viruses to
evade the antiviral response [41,42,43]. In the present study, global
gene expression profiles in CD4+ T lymphocytes were examined in
a unique cohort of 30 HTLV-1 infected individuals from the
Caribbean basin including ATL, HAM/TSP and asymptomatic
carriers (AC) patients. Interestingly, among the many genes
dysregulated in HTLV-1 infected patients, SOCS1 was highly
expressed in CD4+ T cells from HAM/TSP and AC patients, but
not in ATL. Subsequent biochemical analysis demonstrated that
HTLV-1-induced SOCS1 expression played a positive role in viral
replication through inhibition of the IFN response. SOCS1 directly
interacted with IRF3 and promoted its proteasomal degradation in
a SOCS-Box dependent manner, thus identifying a novel
mechanism of HTLV-1 mediated evasion of the IFN response.
Results
Gene expression profiling of CD4+ T cells from ATL,
HAM/TSP and AC patients
To analyze gene expression profiles of CD4+ T cells isolated
from HTLV-1 infected patients, we gathered a unique cohort of
30 HTLV-1 infected individuals from the Caribbean basin,
including 11 AC, 7 ATL, 12 HAM/TSP and 8 healthy, non-
infected donors (NI) (Table S1). Microarray experiments were
performed using the human ImmuneArray cDNA array (UHN
Microarray Center, University of Toronto), followed by higher
order analysis. About three thousand genes were analyzed with
Future Selection Subset/ANOVA on log-transformed data,
followed by unsupervised hierarchical clustering on 1039 genes
selected by Anova analysis (p,0.01) (Figure 1A). These genes
displayed differential expression patterns depending on the type of
HTLV-1-associated disease. Unsupervised clustering based on the
1039 genes signature accurately discriminated between NI,
HAM/TSP and ATL patients. AC samples however did not
separate as an individual cluster, but rather distributed amongst
HAM/TSP and ATL samples. Also, two of the HAM/TSP
patients and two AC clustered with the NI group, suggesting that
the profile of their circulating CD4+ T lymphocytes had not
undergone significant variation compared to healthy donors.
Pair-wise correspondance analysis (PCA) was performed on the
top 500 genes modulated in HTLV-1-infected versus non-infected
samples (p value ,0.01, false discovery rate (FDR) =0.17%)
(Figure 1B). PCA identified prevalent expression profiles among the
three clinical groups, and confirmed significant class discrimination
between non-HTLV-1-infected donors (NI) versus each of the
HTLV-1-associated diseases when plotted in two dimensions
(Figure 1B). Gene clusters common to each HTLV-1-infected
clinical group, and shared within pair-wise comparisons (AC-
HAM/TSP, AC-ATL and ATL-HAM/TSP), could be identified
and are presented in the adjoining Tables of Figure 1B. For each
grouping, genes with a high differential expression are located with
quantitative spacing from the center comparator (gene expressionof
NI group). Specifically, SOCS1 (green square) was identified as a
Author Summary
Infection with HTLV-1 leads to the development of Adult T
cell Leukemia (ATL) or the neurological disorder HTLV-1-
associated myelopathy/tropical spastic paraparesis (HAM/
TSP). Although the majority of HTLV-1–infected individuals
remain asymptomatic carriers (AC) during their lifetime, 2–
5% will develop either ATL or HAM/TSP. Using gene
expression profiling of CD4+ T lymphocytes from HTLV-1
infected patients, we identified Suppressor of cytokine
signaling 1 (SOCS1) as being highly expressed in HAM/TSP
and AC patients. SOCS1 expression positively correlated
with the high HTLV-1 mRNA load that is characteristic of
HAM/TSP patients. SOCS1 inhibited cellular antiviral
signaling during HTLV-1 infection by degrading IRF3, an
essential transcription factor in the interferon pathway.
Our study reveals a novel evasion mechanism utilized by
HTLV-1 that leads to increased retroviral replication,
without triggering the innate immune response.
HTLV-1 Inhibits IFN Signaling by Inducing SOCS1
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agreement with the prior observation by Nishiura et al. [44]. Since
SOCS1 is known to counter-regulate the anti-viral response, it was
selected as a gene of interest for further study.
HTLV-1 infection induces the expression of SOCS1 mRNA
Efficient HTLV-1 spread must overcome cellular antiviral
programs [45]; yet how HTLV-1 evades the host innate immune
response is poorly understood. SOCS1 stood out among the many
genes identified as having the potential to counteract the innate
immune response against HTLV-1. HAM/TSP and AC patients
exhibited a greater than two fold increase in SOCS1 gene expression
compared to NI individuals (Fisher’s test, p value =0.054 and
,0.05, respectively) (Figure 2A). However, no significant difference
in mRNA levels of SOCS1 was found between ATL and NI
patients, suggesting that SOCS1 expression was upregulated in AC
and HAM/TSP. This increase was specific for SOCS1, as SOCS3
mRNA was unchanged in HTLV-1 infected samples compared to
control samples (fold change ,2) (Figure 2B). Using a separate
cohort of patient samples (Table S2), we demonstrated that SOCS1
expression was strongly and positively correlated with HTLV-1
mRNA load in CD4+ T cells of HAM/TSP patients (Pearson’s
p,0.0001) (Figure 2C).
Since high proviral load is a hallmark of HAM/TSP pathology
[46], we investigated the relationship between HTLV-1 replication
and SOCS1 gene expression. Initially, the level of SOCS1 mRNA
was examined in HTLV-1-carrying T cell lines (MT-2, C8166,
MT-4, RMP), control T cell lines (Jurkat and CEM, Figure 2D
and Figure S2), as well as PBMCs infected with the HTLV-1
infectious molecular clone pX1M-TM (Figure 2D and 2E). In
non-leukemic MT-2 cells that carry an integrated replication-
competent provirus and produce infectious HTLV-1 viral
particles, a ,50-fold increase in SOCS1 mRNA was detected,
as compared to non-infected CEM and Jurkat cells (,5-fold). In
leukemic MT-4 and C8166 cells, which carry a defective provirus,
lower levels of SOCS1 mRNA were detected, suggesting that
SOCS1 induction required an intact proviral genome (Figure 2D).
The RMP cell line derived from an ATL patient which express
Figure 1. Expression profiling of genes differentially expressed in HTLV-1 associated-diseases. (A) Unsupervised hierarchical clustering
of the 1039 genes differentially expressed in CD4+ T lymphocytes from 7 ATL, 12 HAM/TSP, 11 AC and 8 NI donors. Significant variation in the
expression pattern of 1039 genes was determined by ANOVA (p,0.01). Each row represents the relative level of expression for a single gene; each
column shows the expression level for a single sample. The yellow and blue colors indicate high and low expression, respectively. Genes were
clustered into 3 groups using a complete linkage and Pearson correlation as distance metric. (B) Pair-wise contrast by Correspondance Analysis (PCA).
PCA analysis was performed on the 1039 genes selected by ANOVA. Correspondence analysis shows genes plotted in discriminate space and
separated into 6 groups: genes associated specifically with ATL, HAM/TSP or AC, and genes commonly regulated in the three groups; AC-HAM/TSP,
AC-ATL or ATL-HAM/TSP. Colored lines denote the direction of class medians and black dots correspond to the genes. Genes with high differential
expression in a group are located far-off the center (gene expression of NI), in the direction determined by the group. The closest to the group line,
the more evident is the associations of the genes with that group. Genes that are down-regulated in this group appear on the opposite site of the
centroid. A short list of the top genes was created by selecting the genes having $2 fold changes relative to NI. The genes lists are ranked by the
absolute variation (Max-Min) in fold change expression among the three HTLV-1 infected groups.
doi:10.1371/journal.ppat.1001177.g001
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(,10-fold). In order to determine whether de novo HTLV-1
infection induced SOCS1 expression, PBMCs expressing the
HTLV-1 infectious molecular clone pX1M-TM (Figure 2E) were
analyzed for the level of SOCS1 and HTLV-1 mRNA at different
times post-transfection. HTLV-1 RNA expression was determined
by amplifying the pX region (tax/rex) of the HTLV-1 proviral
genome; HTLV-1 RNA expression was modest between 24 and
72 h (,10-fold), but the viral mRNA load increased sharply at
96 h (50-fold), concomitent with a dramatic increase in SOCS1
gene expression (,24-fold).
The initial observation that SOCS1 was induced upon HTLV-1
infection prompted us to examine whether SOCS1 also influenced
viral replication. To do so, the effect of SOCS1 expression on
HTLV-1 provirus replication wasexamined in the CEMT cells,co-
expressing a SOCS1 expression vector together with the HTLV-1
provirus. The level of HTLV-1 mRNA was consistently higher in
SOCS1 expressing cells compared to CEM cells expressing HTLV-
1 provirus alone (e.g. 55-fold vs. 10-fold at 24 h) (Figure 3A). As a
complementary strategy, SOCS1 expression was silenced in MT-2
cells(Figure 3B); siRNAs targetingSOCS1(siSOCS1(1) siSOCS1(2)
andsiSOCS1(1)+siSOCS1(2))inhibitedSOCS1levels by50, 75and
90%, respectively. Knock-down of SOCS1 protein expression was
confirmed by immunoblot assay (Figure 3B, bottom panel). Real
time PCR analysis of the HTLV-1 pX region demonstrated a
significant reduction of HTLV-1 mRNA that directly correlated
with the decrease in the observed SOCS1 levels (,27, 56 and 80%
decrease, respectively). These data indicate that SOCS1 induction
during HTLV-1 infection leads to enhanced HTLV-1 replication.
HTLV-1 suppresses type I IFN production
Since SOCS1 has been shown to negatively regulate type I IFN
signaling [34,42], we sought to investigate the relationship
between HTLV-1 infection, type I IFN response and SOCS1
gene expression. First, the profile of type I IFN (IFN-b and IFN-
a2) and IFN-stimulated gene expression (IRF7 and CXCL10) was
examined in PBMCs expressing the HTLV-1 provirus pX1M-TM
(Figure 4A). IFN-b, IFN-a2 and CXCL10 mRNAs were induced
(30, 3.5 and 35-fold, respectively) at 24 h post-HTLV-1 transfec-
tion, and IRF7 mRNA expression (,11-fold) was maximal at
Figure 2. HTLV-1 infection results in the induction of SOCS1 mRNA levels in ex vivo CD4+ T cells and correlates with HTLV-1 mRNA
expression. (A, B) Comparison of mRNA expression of SOCS1 and SOCS3 in CD4+ T cells from HTLV-1 infected and NI patients. CD4+ T cells were
isolated from PBMCs of HTLV-1 infected and NI patients; SOCS1 (A) and SOCS3 (B) mRNA levels were assessed using a human cDNA array. SOCS1 gene
expression was stratified by clinical status forming 4 groups: NI, ATL, AC and HAM/TSP. Each point represents SOCS level from one individual, with
black bars showing median value in each group. Mann-Whitney test was used to compare intensity of SOCS expression between groups (*, p,0.05;
***, p,0.001). (C) Expression of SOCS1 mRNA levels correlated with HTLV-1 mRNA load in HAM/TSP patients. CD4+ T cells from HAM/TSP and NI
patients were lysed and total RNA was subjected to reverse transcription. cDNA was analyzed by quantitative real time PCR to assess mRNA levels of
SOCS1 and HTLV-1 (Pearson’s correlation p,0.0001, line represents log-log non-linear fit of the data) (D) Expression of SOCS1 and HTLV-1 mRNAs was
measured in HTLV-1-carrying T cell lines (MT-2, MT-4, C8166, RMP) vs. HTLV-1-negative T cell lines (CEM, Jurkat). Cells were treated as previously and
cDNA was analyzed by quantitative real time PCR to measured SOCS1 and HTLV-1 gene expression. Equivalent mRNA amounts were normalized to
GAPDH gene expression and calculated as fold change with the levels of uninfected CEM cells set arbitrarily as 1. (E) PBMCs from healthy individuals
were electroporated with either HTLV-1 provirus (pX1M-TM) or control empty vector (ctl). At the indicated times, total RNA was extracted and
analyzed for SOCS1 and HTLV-1 gene expression. Equivalent mRNA amounts were normalized to GAPDH mRNA expression and calculated as fold
change from the levels of control cells that were arbitrarily set as 1.
doi:10.1371/journal.ppat.1001177.g002
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substantially (below 50% of maximal levels) by 48–72 h. At 96 h,
when HTLV-1 and SOCS1 gene expression were maximal, no
reactivation of antiviral gene transcription was detected (Fig 2D
and 4A). We interpret this result as indicating that early after
infection, transient stimulation of the antiviral response occurs and
restricts de novo HTLV-1 RNA expression; at 72–96 h after
infection induction of SOCS1 results in the shutdown of the type I
IFN response, thus promoting high HTLV-1 mRNA expression.
IFN-a signaling is initiated by binding to the heterodimeric
IFN-a receptor, followed by activation of JAK1 and TYK2
protein kinases, resulting in the phosphorylation of STAT1 and
STAT2 [31]. To investigate whether HTLV-1 expression
interfered with the type I IFN response, primary PBMCs
expressing the HTLV-1 provirus pX1M-TM were treated with
IFN-a for 10–120 min to focus on early IFN-triggered phosphor-
ylation events. In control PBMCs, STAT1 and JAK1 phosphor-
ylation was detected at 10 and 20 min post-IFN-a treatment,
as determined by immunoblotting with specific antibodies
(Figure 4B). However, in PBMCs expressing the proviral clone
pX1M-TM, IFN-a-induced phosphorylation of JAK1 and STAT1
was reduced .90 and 70%, respectively (Figure 4B), while total
protein levels of JAK1 and STAT1 remained unchanged in
control and HTLV-1 expressing PBMCs.
To further characterize the effect of HTLV-1 on antiviral
response, PBMCs expressing the HTLV-1 provirus were infected
with Sendai virus (SeV) - a strong inducer of the antiviral response
- and kinetics of expression of IFN genes was assessed by Q-PCR
(Figure 4C, D, E). At 24 h post-transfection, PBMCs had
significant HTLV-1 proviral load (,700 fold higher than control,
Figure 4C); thus at this time, PBMCs were infected with SeV (20
HAU/mL) to compare the levels IFN-a2 and IFN-b mRNA in the
presence or absence of HTLV-1 provirus (Figure 4D and E).
Induction of IFN-b and IFN-a2 mRNA was detected in all PBMCs
as early as 3 h post-SeV infection and was sustained up to 12 h
(Figure 4D and E). However, in HTLV-1 expressing PBMCs,
induction of IFN-b and IFN-a2 mRNA was reduced .60%,
relative to the level observed in the absence of HTLV-1 provirus.
Decreased levels of IFN-b and IFN-a2 in cells expressing the
HTLV-1 provirus were not due to inhibition of SeV replication, as
demonstrated by immunoblot for SeV proteins (Figure 4F).
Similarly, knockdown of SOCS1 in MT-2 cells reversed the
inhibition of antiviral gene expression imposed by HTLV-1
(Figure 5). Pooled siSOCS1 resulted in increased IFN-b (7.5-fold),
ISG56 (2.5-fold), IFN-c (4-fold) and CXCL10 (,10-fold) gene
expression compared to control siRNA. These results demonstrate
that SOCS1 contributes to the inhibition of antiviral responses
during HTLV-1 infection.
HTLV-1-mediated SOCS1 expression induces
proteasomal degradation of IRF3
Many pathogenic viruses strategically antagonize the early
innate antiviral defenses in order to maintain viral replication,
often inactivating IFN signaling components as part of their
immune evasion strategy (reviewed in [45]). Because IRF3 is
essential for IFN gene activation, we assessed IRF3 dimerization
(as a measure of activation) in PBMCs expressing the HTLV-1
provirus (Figure 6A). In control PBMCs, SeV infection induced
IRF3 dimer formation at 3–12 h post-infection, whereas IRF3
dimer formation was not detected in PBMCs expressing the
HTLV-1 provirus. Furthermore, IRF3 monomer levels decreased
sharply during the course of HTLV-1 replication (Figure 6A).
Immunoblot analysis for total IRF3 confirmed that IRF3 levels
decreased in a time dependent manner in PBMCs and Jurkat cells
expressing the HTLV-1 provirus, a phenomenon not observed in
control PBMCs infected with SeV (Figure 6C). IRF-3 was
degraded via the proteasomal pathway, as the use of the
proteasome inhibitor MG132 prevented HTLV-1 mediated
reduction of IRF3 protein level (Figure 6B). This observation
demonstrates for the first time that HTLV-1 does not activate
IRF3 in PBMCs, but rather prevents the initial steps of type I IFN
production by targeting IRF3 for proteasomal degradation.
Additionally, IRF3 silencing in Jurkat cells expressing the
HTLV-1 provirus resulted in increased HTLV-1 mRNA expres-
sion (Figure 6D) – indicating that the degradation of IRF3 by
SOCS1 enhances viral mRNA load.
Given that SOCS1 upregulation during HTLV-1 infection
inhibits the expression of IFN and ISGs, we sought to investigate
Figure 3. SOCS1 promotes HTLV-1 mRNA synthesis. (A) CEM cells
were transfected with pX1M-TM alone or co-transfected with pX1M-TM
and Myc-tagged SOCS1 expression vectors. At 24 h post-transfection,
total RNA was extracted and evaluated for HTLV-1 (A) gene expression
by real time PCR. Equivalent mRNA amounts were normalized to
GAPDH mRNA expression and calculated as fold change of the levels of
control cells which were arbitrarily set as 1 (*** p,0.001). (B) Depletion
of SOCS1 decreases HTLV-1 mRNA synthesis in MT-2 cells. MT-2 cells
were electroporated with control or SOCS1 specific-siRNAs (siSOCS1 (1),
siSOCS1 (2), or a pool of both siSOCS1 (1) and siSOCS (2)). At 72 h post-
transfection, total RNA was extracted and analyzed for HTLV-1 and
SOCS1 mRNA levels. MT2 cells were treated as in B; cells lysates were
prepared at 72 h post-electroporation, and equal amounts of protein
(20 mg) were resolved by SDS-PAGE followed by immunoblotting
against SOCS1, with b-actin shown as a loading control (bottom panel).
doi:10.1371/journal.ppat.1001177.g003
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HEK293T cells expressing increasing amounts of SOCS1 together
w i t hac o n s t a n ta m o u n to fI R F 3 ,S O C S 1e x p r e s s i o ni n d u c e dI R F 3
degradation in a dose-dependent manner (Figure 7A). RT-PCR
analysis with specific IRF3 primers showed that the level of IRF3
mRNA remained unchanged, indicating that SOCS1 had no effect
on IRF3 gene expression (Figure 7A). Moreover, SOCS1 silencing in
HTLV-1 infected MT-2 cells restored endogenous IRF3 expression
(Figure S3). Interestingly, the addition of the proteasome inhibitors
lactacystin (Figure 7B) or MG132 (data not shown) prevented IRF3
degradation in the presence of SOCS1. Furthemore, co-immuno-
precipitation experiments demonstrated that SOCS1 physically
interacted with IRF3 (Figure 7C), indicaing that IRF3 degradation
was triggered by physical association with SOCS1.
SOCS1 induces degradation of target proteins by recruiting
Elongin B/C to its SOCS-Box domain, leading to the formation of
an E3 ubiquitin ligase complex able to modify substrate proteins
with K48-linked ubiquitin chains. To confirm that SOCS1-
mediated IRF3 degradation required E3 ligase complex activity,
increasing amounts of a SOCS1 deletionmutantlacking the SOCS-
Box - SOCS1-DB/C-Box - was expressed together with a constant
amount of IRF3 (Figure 7D); SOCS1-DBC did not induce IRF3
degradation at any concentration (compare Figures 7D and 7A).
Proteasome-mediated degradation requires the addition of K48-
polyubiquitin chain to the target protein; exogenous addition of
ubiquitin mutated in its ability to link K48-polyubiquitin chains
(ubiquitin-K48R, which contains a single K48R point mutation,
or Ubi-KO, which contains no lysines) prevented IRF-3degrada-
tion, while HEK293 cells expressing exogenous SOCS1 readily
degraded IRF3 (Figure 7E). In addition, IRF3 turnover was
completely reversed in the presence of a 10-fold excess of HA-Ub
K48R or HA-Ub KO (Figure 7E), thus confirming that
proteosome-mediated IRF3 degradation by SOCS1 requires
recruitment of Elongin B/C E3 ligase machinery and is dependent
on K48-polyubiquitin chain formation.
Discussion
The complexity of gene expression dysregulation in ATL or
HAM/TSP diseases has been highlighted in a number of gene
Figure 4. HTLV-1 infection results in the inhibition of type I IFN gene expression. (A) PBMCs from healthy individuals were electroporated
with either HTLV-1 provirus (pX1M-TM) or control empty vector (ctl). At the indicated times, total RNA was extracted and analyzed for, IFN-b, IRF7, IFN-
a2, CXCL10 (A) gene expression. Equivalent mRNA amounts were normalized to GAPDH mRNA expression and calculated as fold change from the
levels of control cells that were arbitrarily set as 1. (B) HTLV-1 inhibits IFN-a-induced tyrosine phosphorylation of JAK1 and STAT1. PBMCs were
electroporated as in (A) and 48 h post-transfection cells were left-untreated or treated with 1000U/ml IFN-a. Cells lysates were prepared at indicated
times and equal amounts of protein (50 mg) were resolved by SDS-PAGE followed by immunoblotting against Tyr-701-phosphorylated STAT1, total
STAT1, Tyr-1022/1023-phosphorylated JAK1, total JAK1, with b-actin shown as a loading control. (C, D, E, F) HTLV-1 inhibits SeV-mediated type I IFN
gene expression. PBMCs were electroporated with either HTLV-1 provirus (pX1M-TM) or control empty vector for 24 h prior to SeV infection. Total
RNA was extracted at the indicated times and analyzed for HTLV-1 (C), IFN-b (D) and IFNa2 (E) mRNA levels by real time PCR. Equivalent mRNA
amounts were normalized to GAPDH mRNA expression and calculated as fold change from the expression levels of control cells that were arbitrarily
set as 1 (**, p,0.05; *** p,0.001). (F) PBMCs were treated as in C, D, E; cells lysates were prepared at 3–48 h post-SeV infection, and equal amounts of
protein (20 mg) were resolved by SDS-PAGE followed by immunoblotting with anti-SeV antisera. Immunoblotting against b-actin is shown as a
loading control.
doi:10.1371/journal.ppat.1001177.g004
Figure 5. SOCS1 suppresses the antiviral response. Depletion of
SOCS1 restores the type I and II IFN signaling in MT-2 cells. MT-2 cells
were electroporated with control or SOCS1 specific-siRNAs (siSOCS1 (1),
siSOCS1 (2), or a pool of siSOCS1 (1) and siSOCS1 (2)). At 72 h post-
transfection, total RNA was extracted and analyzed for IFN-b, ISG56,
CXCL10 and IFN-c mRNA levels.
doi:10.1371/journal.ppat.1001177.g005
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present study however represents the first comparative genome-
wide array analysis to establish gene expression profiles for HTLV-
1-associated disease states. With a unique cohort of 30 HTLV-1-
infected individuals from the Caribbean basin and a custom
ImmuneArray [50], we identified ,1039 significant immune-
related genes that were differentially regulated in CD4+ T cells
from 11 AC, 7 ATL, 12 HAM/TSP patients, compared with
CD4+ T cells from 8 NI donors from the same geographical
region. Clear clinical discrimination was observed between the
ATL, HAM/TSP and NI patients, both by unsupervised
hierarchical cluster and principal component analysis. Our
analysis revealed that the gene expression profile in ATL cells
was clearly distinct from healthy CD4+ T cells, although
similarities in gene expression patterns were observed between
HAM/TSP samples and NI controls. This difference between
HAM/TSP and ATL CD4+ T cells likely reflects numerous
alterations in gene expression that occur during ATL transforma-
tion [12]. In contrast, evolution to HAM/TSP does not involve
cellular transformation, but rather is characterized by a high
HTLV-1 proviral load and the establishment of a pro-inflammatory
microenvironment due to cytokine/chemokine production of
infected and bystander immune cells. It is possible that T
lymphocytes derived from early-stage HAM/TSP patients have a
profile similar to healthy cells and that gene expression changes are
observed only at later stages of the disease, an interesting hypothesis
that needs to be investigated further. Interestingly, AC patients did
not cluster as an individual group but rather distributed amongst
NI, ATL and HAM/TSP patients, suggesting that extensive
analysis of the genes modulated in NI, HAM/TSP and/or ATL
groups may help to identify candidate genes important for early
diagnosis of HTLV-1 diseases. Here, the major cellular pathways
identified involved cell adhesion (CXCR4, CD2, CD63), antimi-
crobial defense (KLRB1, SPN, SELPLG), innate immune signaling
(SOCS1, TRAF3, AIM2, TLR2, IKBKG, STAT3), antigen
presentation (TRA alpha locus), and chemotaxis (CCL14, SPN,
Figure 6. HTLV-1 induces degradation of endogenous IRF3. (A). PBMCs from healthy individuals were electroporated with either HTLV-1
provirus (pX1M-TM) or empty vector. PBMCs transfected with the control vector were subsequently infected with SeV. At the indicated times, lysates
from transfected or infected PBMCs were electrophoretically resolved under non-denaturing or denaturing conditions. Western blot analysis was
used to locate monomer and dimer forms of IRF3 in the non-denaturing gel (upper panel), and global IRF3 protein in the denaturing gel (lower
panel). Immunoblotting against b-actin was used as a loading control. Total IRF3 protein expression levels (upper band) were quantified and
normalized to b-actin levels using the Scion Image 4.0 software program. (B) Degradation of IRF3 is inhibited by the proteasome inhibitor (MG132).
PBMCs were treated as indicated in (A). At 48 h post-HTLV-1 provirus, cells were incubated with 5 mM of MG132 for 6 h. Cells lysates were prepared
and equal amounts of protein (20 mg) were resolved by SDS-PAGE followed by immunoblotting against IRF3, with b-actin shown as a loading control.
(C) Same experiments and analysis for IRF3 dimerization were performed in the Jurkat leukemic T cell line. (D) Loss of IRF3 enhances HTLV-1 mRNA
load in infected T cells. Jurkat cells were electroporated with control or a pool of IRF3 specific-siRNAs, and re-transfected at 24 h with HTLV-1 provirus
(pX1M-TM) vector. At 72 h post-transfection, total RNA was extracted and analyzed for HTLV-1 mRNA levels. Cells lysates were prepared at 72 h post-
electroporation, and equal amounts of protein (20 mg) were resolved by SDS-PAGE followed by immunoblotting against IRF3, with b-actin shown as a
loading control.
doi:10.1371/journal.ppat.1001177.g006
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PLoS Pathogens | www.plospathogens.org 7 November 2010 | Volume 6 | Issue 11 | e1001177Figure 7. IRF3 interacts with SOCS1 and undergoes SOCS1-mediated degradation and ubiquitination. (A) HEK293 T cells co-transfected
with increasing amounts of SOCS1 promotes degradation of IRF3 in a concentration-dependent manner. HEK293 T cells were co-transfected with
Flag-tagged IRF3 and increasing amount of Myc-tagged SOCS1 expression vectors. Cells were collected 24 h post-transfection for either RNA
extraction or whole cell extract (WCE) preparation. Immunoblot analysis for SOCS1 and IRF3 protein expression was performed by incubating with
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immune system during HTLV-1 infection.
Among the many genes modulated during HTLV-1 infection, the
suppressor of the interferon signaling - SOCS1 - was upregulated in
HAM and AC patients but not in ATL. This observation is in
agreement with a previous report published by Nishiura et al.
demonstrating that SOCS1 mRNA levels were increased in HAM/
TSP patients compared to NI [44]. We now demonstrate that CD4+
T cells from HAM/TSP and AC patients express increased levels of
SOCS1 which strongly correlates with HTLV-1 mRNA load. Since
HAM/TSP patients are characterized by a very high proviral load,
we hypothesized that SOCS1 upregulation in HAM/TSP may
represent an immune evasion strategy used by HTLV-1 to dampen
the early IFN antiviral response. Indeed, in PBMCs expressing a
HTLV-1 infectious molecular clone, and in cell lines harboring an
intact HTLV-1 provirus, high levels of SOCS1 gene expression
correlated with high levels of HTLV-1 transcription. Increasing
HTLV-1 proviral expression blocked expression of type I IFN genes
such as IFN-b,I R F 7 ,I F N - a2,a sw e l la st h eI F N - c stimulated
chemokine gene CXCL10, with maximal inhibition observed when
HTLV-1 and SOCS1 gene expression levels were coordinately
elevated. Furthermore, depletion of SOCS1 using siRNA decreased
HTLV-1 replication and restored the type I IFN response.
IFN-a/b is known to have a negative impact on retrovirus
replication. Although few studies have reported its effect on
HTLV-1, type I IFN constitutes a potent anti-retroviral mecha-
nism that limits HTLV-1 replication [22,23]. Moreover, clinical
studies using IFN-b therapy in HAM/TSP patients have
demonstrated benefits in reducing HTLV-1 mRNA load and the
number of pathogenic CD8+ T cells, as well as minimizing disease
progression during therapy [51]. Accumulating evidence indicates
that HTLV-1 possesses evasion mechanisms to counteract type I
IFN signaling: for example, HTLV-1 down-regulates JAK-STAT
activation by reducing phosphorylation of Tyk2 and STAT2,
possibly through a Gag- or Pr-mediated mechanism [52]; and Tax
further negatively modulates IFN-a-induced JAK/STAT signaling
by competing with STAT2 for CBP/p300 coactivators [53].
SOCS1 is a cytokine-inducible intracellular negative regulator that
inhibits type I and II IFN signaling by triggering the degradation of
various components of the JAK-STAT cascade (reviewed in [32,54]).
SOCS1 can also be induced during virus infection and plays a
positive role in viral replication [55,56,57]. SOCS1 is induced during
virus infection and binds directly to the type I IFN and/or II IFN
receptors to suppress IFN signaling, thereby preventing chronic
inflammation. However, SOCS1could be subverted to enhance viral
replication via untimely inhibition of the IFN response. SOCS1
induction may be a direct result of viral protein activity. Bioinfor-
matics analysis of the SOCS1 promoter region reveal the presence of
CRE, AP-1 and NF-kB binding regions, suggesting the possible
involvement of HTLV-1 Tax in the induction of SOCS1 expression
(data not shown). Another possibility is that SOCS1 transcriptional
activation is not directly regulated by viral proteins, but rather by
recognition of viral RNA and downstream signaling events. For
instance, Potlichet et al. reported that Influenza A virus suppresses the
antiviral response by inducing SOCS1 and SOCS3 via TLR3-
independent but RIG-I/IFNAR dependent pathways [43]. More-
over, IFN-c gene expression in CD4+ T cells from HAM/TSP
patients is elevated as compared to ATL or AC patients. Constitutive
induction of IFN-c may also augment SOCS1 expression, and thus
increase HTLV-1 replication.
SOCS proteins exert their negative effect by promoting the
ubiquitination and proteosomal degradation of key proteins
involved in cytokine signaling pathways: MAL in Toll like receptor
4 signaling (TLR4), JAK2 in IFN-c mediated signaling and NF-kB
p65/RelA are all known targets of SOCS1 [38,58,59]. Here, we
identified IRF3 as an important target for SOCS1-induced
proteasomal degradation that impacts the early type I IFN
antiviral response. IRF3 is ubiquitously expressed in the cytoplasm
and is activated in response to viral infection, triggering IFN-b and
other early ISGs expression, thus initiating the antiviral response.
To counter type I IFN, many viruses have evolved strategies to
interfere with IRF3 activation as an efficient means to limit IFN-b
production [26,60]. Interference of IRF3 activation also dampens
the second wave of IFN signaling, including production of IFN-a.
The mechanisms of IRF3 antagonism vary, and include inhibition
of IRF3 phosphorylation, nuclear translocation, or transcription
complex assembly as well as down-regulation of IRF3 by
ubiquitin-mediated degradation. In this context, bovine herpes
virus 1 infected cell protein 0 (bICP0) has been shown to act as an
E3 ligase and promote IRF3 degradation in a proteasome-
dependent manner, thus inhibiting the IFN response [61].
The interaction between SOCS1 and IRF3 during HTLV-1
infection promotes proteasome-mediated degradation of IRF3 and
thus abrogates early IFN antiviral signaling. SOCS1-dependent
IRF3 degradation required the elongin B and C binding sites
within SOCS1 and K48-linked polyubiquitination of IRF3.
Indeed, the SOCS box-mediated function of SOCS1 is chiefly
exerted via its ubiquitin ligase activity [62] and biochemical
binding studies have shown that the SOCS box interacts with the
elongin B/C complex, a component of the ubiquitin/proteasome
pathway that forms an E3 ligase with Cul2 (or Cul5) and Rbx-1
[40,58]. Thus, SOCS1 serves as an adaptor to bring target
proteins to the elongin B/C-Cullin E3 ligase complex for
ubiquitination. Although we show from our current experiments
that SOCS1 directly mediates K48-linked ubiquitination of IRF3,
further studies are required to elucidate the details of SOCS1-
mediated IRF3 ubiquitination, as well as the mechanisms of
regulation of SOCS1 during HTLV-1 infection.
The present study reveals a novel mechanism of viral evasion of
the IFN response in HTLV-1 infected T lymphocytes – the
antibodies against Myc, Flag, or b-actin, respectively (upper panel). RNA (1 mg) from each sample was subjected to RT-PCR for selective amplification
of specific IRF3 mRNA and the constitutively expressed b-actin, as a control. PCR products were separated on a 2% agarose gel and visualized with
ethidium bromide staining (lower panel). (B) Degradation of IRF3 is inhibited by the proteasome inhibitor (lactacytin). HEK293 T cells were co-
transfected with expression vectors as indicated in (A) and incubated with 10 mM of lactacystin. Twenty four hours post-transfection equal amounts
of proteins (30 mg) were resolved by SDS-PAGE followed by immunoblotting with antiserum specific for Flag and Myc. Immunoblotting against b-
actin was performed as loading control. (C) Interaction between IRF3 and SOCS1. HEK293 T cells were co-transfected with expresssion vectors for
Myc-tagged SOCS1 and Flag-tagged IRF3; at 24 h post-transfection, cells lysates were immunoprecipitated with Flag or Myc antibodies, and the
precipitates were immunoblotted to assess Flag and Myc proteins expression. (D) IRF3 is degraded in a SOCS-Box-dependent manner. HEK293 T cells
were co-transfected with Flag-tagged IRF3 and increasing amount of a deletion mutant of SOCS1 (SOCS1-DBC-Box) expression vectors. Cells were
collected 24 h post-transfection for WCE preparation. Immunoblot analysis for SOCS1 and IRF3 protein expression were performed and incubated
with antibodies against SOCS1, Flag, or b-actin, respectively. (E) SOCS1 mediated IRF3 ubiquitination. HEK293 T cells were co-transfected with Flag-
tagged IRF3, Myc-tagged SOCS1 and either KO or K48R ubiquitin mutant expression vectors. Cells were collected 24 h post-transfection for WCE
preparation. Immunoblot analysis for IRF3, SOCS1, Ub protein expression were performed and incubated with antibodies against Myc, Flag, Ha or b-
actin, respectively.
doi:10.1371/journal.ppat.1001177.g007
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HTLV-1 replication in patients suffering from HAM/TSP. Future
studies are required to elucidate putative alternate consequences of
SOCS1 upregulation in T cells [63], as well as the effect of HTLV-
1 induced SOCS1 expression in other relevant viral reservoirs
such as dendritic cells and astrocytes [64,65]. Collectively,
SOCS1-mediated degradation of IRF3 during HTLV-1 infection
has substantial implications in the framework of known HTLV-1
pathobiology and as such opens new avenues of exploration for
designing effective therapeutic strategies.
Materials and Methods
Ethics statement
Blood samples from HTLV-1 infected patients and non-infected
(NI) donors were obtained from the Centre Hospitalier Uni-
versitaire de Fort-de-France in Martinique and Institut Pasteur de
Cayenne in French Guyana. Patients suffering from ATL, HAM/
TSP or HTLV-1 asymptomatic carriers were recruited according
to World Health Organization (WHO) criteria. According to the
French Bioethics laws, the collection of samples from HAM/TSP,
ATL, AC and NI has been declared to the French Ministry of
Research and the study was reviewed and approved by the CPP
(Comite ´ de Protection des Personnes) Sud-Ouest/Outre-Mer III,
as well as the ARH (Agence Re ´gionale de l’Hospitalisation) from
Martinique. Because the protocol is non-interventional (e.g. blood
samples collected for routine health care with no additional
samplings or specific procedures for subjects), no informed consent
was provided by the patient, as stated by the French Public Health
code and therefore the study was conducted anonymously. Clinical
collection of samples for research purpose are stored at the Centre
de Ressources Biologiques de Martinique (CeRBiM). The
CeRBiM database has been approved by the CNIL (Commission
nationale de l’informatique et des liberte ´s). Leukophoresis from
healthy donors were also obtained at the Royal Victoria Hospital,
Montreal, Quebec, Canada. Informed consent were written and
provided by study participants in accordance with the Declaration
of Helsinki. The study was reviewed and approved by the Royal
Victoria Hospital, the Jewish General Hospital, and McGill
University Research Ethics Committee (REC) board of the
SMBD-Jewish General Hospital.
Patient samples
In total, we selected for study 12 HAM/TSP, 11 asymptomatics
(AC), 7 ATL and 8 not infected individuals (NI). The diagnosis of
the 7 ATL cases included in patient cohort number 1 respected the
international consensus recently published by Tsukasaki et al. [7].
Diagnostic criteria for ATL included serologic evidence of HTLV-1
infection, and cytologically or histologically proven T cell
malignancy. Six ATL cases were classified as acute leukemia type
on the basis of leukemic manifestations, with .5%typical ATL cells
in the peripheral blood, and immunologically confirmed mature
CD4+ T cell phenotype. One case (HISS0023) was a lymphoma
type, with ,5% circulating abnormal cells, the ATL cell phenotype
and clonal integration of HTLV-1 being confirmed on lymph node
tissue. Diagnosis of HAM/TSP was in accordance with WHO
criteria [66], which comprise (1) slowly progressive spastic
paraparesis with symmetrical pyramidal signs, (2) disturbance of
bladderfunction,(3)noradiologicevidenceofsignificantspinal cord
compression, and (4) intra-thecal synthesis of anti2HTLV-1
antibodies. The asymptomatic HTLV-1 carriers did not display
any neurological symptoms (Tables S1 and S2). PBMCs were
isolated by centrifugation (400 g at 20uC for 25 min) on a Ficoll-
Hypaque gradient (GE Healthcare Bio-Sciences Inc., Oakville,
Canada). CD4+ T lymphocytes were isolated using a negative
selection CD4 enrichment cocktail with the high-speed autoMACS
system (Miltenyi Biotec) according to the manufacturer’s instruc-
tions. In all cases, the purity of CD4+ T lymphocytes was between
90 and 95% as determined by flow cytometry. Cells were pellet and
kept at 280uC until all samples were ready for RNA extraction.
Cell lines and reagents
The HTLV-1-carrying T cell lines MT-2, MT-4, C8166, RMP
and the HTLV-1-negative T cell lines CEM and Jurkat were used
for experiments. MT-2, MT-4 and C8166 cells are derived from
umbilical cord blood lymphocytes after cocultivation with leukemic
cells from ATL patients [67]. MT-2 cells are reported to have
integrated at least fifteen copies/cell, including defective types, of
HTLV-1 proviral DNA whereas C8166 cells have only one copy of
proviral DNA integrated in the genome [68,69]. The interleukin
(IL-2)-independent RMP cell line is derived from CD4+ T cell of a
patient with acute ATL. All cell lines were maintained in RPMI
1640 medium supplemented with 10% heat-inactivated fetal bovine
serum, 100 U/ml penicillinG, and 100 mg/ml streptomycin.
HEK293T cells were used for transient transfection and were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum,
100U/ml penicillin G, and 100 mg/ml streptomycin.
For proteasome inhibitor treatment, MG132 (Sigma-Aldrich) or
Lactacystin (Boston Biochem) were used at 5 and 10 mM,
respectively. Sendai virus CANTELL strain (SeV) was obtained
from Charles River Laboratory (North Franklin, CT). Cells were
infected with SeV at 20 hemagglutinating units (HAU) per 10
6
cells in serum-free medium supplemented with 10% heat-
inactivated fetal bovine serum 2 h postinfection and harvested
for whole cell extracts or RNA extraction at indicated times.
Plasmids
The HTLV-1 proviral clone pX1M-TM was kind gift from Dr
David Derse (National Cancer Institute-Frederick, Frederick, USA).
Myc-tagged SOCS1 full length and the deletion mutant SOCS1-
DBCBox (amino acids 174–183) were kind gifts from Dr. Ferbeyre
Gerardo (Departement de Biochimie, Universite de Montreal,
Canada). Ha-Ub-K48R and Ha-Ub-KO were kind gifts from Dr.
Zhijan Chen (Department of Molecular Biology, University of Texas
Southwestern Medical Center, Dallas, Texas). Plasmid encoding for
Flag-tagged IRF3 full length was decribed previously [27].
RNA isolation, amplification, and hybridization
Total RNA was extracted using Trizol Reagent (Invitrogen) or
RNeasy kit (Qiagen) according to the manufacturer’s instructions.
The RNA integrity and purity was assessed with the Agilent 2100
Bioanalyzer (Agilent Technologies). Total RNA was amplified
using the MessageAmp II mRNA kit (Ambion, Austin, USA).
Sample and universal human RNA probes (Stratagene) for
microarray hybridization were prepared by labeling the amplified
RNA with Cy5 or Cy3, respectively, by reverse transcription, and
hybridizing the labeled cDNA on the CANVAC (http://www.
canvac.ca/) human Immunoarray version 2 manufactured by the
Microarray Center (UHN, Toronto, ON, Canada) containing
7256 duplicate spots representing 3628 expressed sequence tags
(ESTs). Details of the labeling and hybridization procedures can
be obtained at http://transnet.uhnres.utoronto.ca.
Microarray analysis
Microarrays were scanned using Scanarray Express Scanner
(Packard Biosciences) or the Axon 4000B scanner at 10-mm
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spots and flagged for omission. Quantified raw data was acquired
with QuantArray version 3 and saved as quantarray text files. The
quantified raw data were managed and pre-processed in
GeneTraffic (Iobion Informatic). Following background correction
and removal of genes where both channels were less than 100 or
represented by less than 90% of the samples and polished data was
generated by normalization by Lowess sub-grid. The final data
array was analyzed using JExpress Pro software (http://www.
molmine). To establish differentially expressed genes, multi-class
analysis was performed by one-way ANOVA on Log2 fold change
(Log2Fc) data for ATL, HAM/TSP, AC and NI groups. Genes
with a p value #0.01 were selected as significant (1039 total).
Visualization was produced by unsupervised clustering of the 1039
genes using Pearson correlation parameters. Pair wise correspon-
dance analysis (PCA) was performed on the first 500 genes by
Future Subset Selection (FSS) t-test. Genes were selected based on
false discovery rate (FDR) according to the Benjamini/Hochberg
(BH) methods. Gene annotations were gathered using manual
searches in NCBI as well as the ontology tools DAVID (http://
david.abcc.ncifcrf.gov/) and BioRag (Bioresource for array genes,
http://www.biorag.org). Fold change (Fc) for each gene was
calculated as 2
(Log
2
X-Log
2
NI), where Log2 X represents the Log2
(Fc) for either ATL, AC or HAM and Log2 NI represents the Log2
(Fc) for NI. Microarray data have been deposited in the NCBI
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/).
The results of the microarray experiment were confirmed by
quantitative PCR (Q-PCR) on 47 genes chosen on the basis of a
fold change of at least 2-fold, with RNA from 3 patients per group
used for validation. A strong correlation between the average fold-
change determined by microarray and the average of the qPCR
results was observed, with 25/47 genes having a Pearson
correlation value of at least 0.6 (Figure S1A, B, C) and 18/47
genes with a value of at least 0.9 (Figure S1A).
Transfection of primary PBMCs with HTLV-1 proviral
clone
Leukophoresis from healthy donors were obtained at the Royal
Victoria Hospital, Montreal, Quebec, Canada. PBMCs were
isolated by Ficoll-Hypaque gradient (GE Healthcare Bio-Sciences
Inc., Oakville, Ontario, Canada) and activated for 4 days with
2 mg/ml of phytohemagglutinin-P (PHA-P) (Sigma Aldrich) and
50 U of interleukin 2 per ml (IL-2) (PBL Biomedical Laboratories).
5 mg of pX1M-TM was pulsed into 10610
6 cells PBMCs in a 0.4-
cm cuvette using a Gene Pulser II (Bio-Rad Laboratories) set at
0.25 kV and 0.95 mF. Cells were plated in six-well plates in
complete medium and collected at indicated times for whole cell
extracts or RNA extraction.
Real time PCR analysis
Validation of selected target genes was performed by relative
quantification PCR (RQ-PCR) in 9 samples (3 NI, 3 ATL, 3
HAM). A total of 2 mg of amplified RNA from uninfected and
HTLV-1-infected samples was converted to cDNA using the High
Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA)
according to the manufacturer’s protocol. cDNA was amplified
using SyBR Green I PCR master mix (Roche Applied Science,
Germany) or TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, CA, USA). Real-time PCR primers were
designed using the primer3 website (primer3_www.cgiv. 0.2) and
listed in Supporting information (Table S3). Some predesigned
primers and probe sets from TaqMan (Applied Biosystems) were
also used and listed in Table S3. Data were then collected using
the AB 7500 Real-Time PCR System (Applied Biosystems, Foster
City, CA) and analyzed by comparative CT method using the SDS
v1.3.1 Relative Quantification (RQ) Software where ddCT =
dCT(Sample) – dCT (non-infected), dCT (Sample) = CT
(Sample) - CT (GAPDH) and dCT (non-infected) = CT (non-
infected) - CT (GAPDH).
Immunoblot analysis and dimerization assay
Cells destined for immunoblotting were washed with PBS and
lysed in lysis buffer (0.05% NP-40, 1% glycerol, 30 mM NaF,
40 mM b-glycerophosphate, 10 mM Na3VO4, 10 ng/ml of
protease inhibitors cocktail (Sigma Aldrich, Oakville, Ontario,
Canada). The protein concentration was determined by using the
Bradford assay (Bio-Rad, Mississauga, Canada). Whole-cell extracts
(30 mg) were resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) in a 10%-acrylamide gel and trans-
ferred to a nitrocellulose membrane (Bio-Rad, Mississauga,
Canada). Membranes were blocked in 5% nonfat dried milk in
Tris-buffered saline (TBS) plus 0.1% Tween 20 for 1 h at room
temperature. Membranes were then probed overnight with
antibodies against Stat 1 phosphorylated (Tyr701) (1:1000; Cell
Signaling) and non-phosphorylated forms (p91) (1 mg/ml; Santa
Cruz); phosphorylated Jak1 (Tyr 1022/1023) (1:1000; Cell
Signaling); total Jak 1 (1 mg/ml Santa Cruz); SeV (1:10,000);
SOCS1 (1 mg/ml; Zymed laboratories), IRF3 (1:10,000; IBL,
Japan) in 5% bovine serum albumin and PBS at 4uC. Incubation
mixtureswere washedinTBS-0.05% Tween 20fivetimesfora total
of 25 min. Following washes, the membrane was incubated with
peroxidase-conjugated goat anti-rabbit or anti-mouse antibody
(KPL, Gaithersburg, MD) at a dilution of 1:5,000 for 1 h at room
temperature.Followingthe incubation withthesecondaryantibody,
membranes were washed again (5 times, 5 min each) and then
visualized with an enhanced chemiluminescence (detection system
as recommended by the manufacturer (ECL; GE Healthcare Bio-
Sciences Inc., Oakville, Ontario, Canada).
Native-PAGE was conducted as described [70]. Briefly, 10 g
WCE in native sample buffer (62.5 mMTris-HCl, pH 6.8, 15%
glycerol, and bromophenol blue) were resolved by electrophoresis
on a 7.5% acrylamide gel (without SDS) pre-runned for 30 min at
40 mA using 25 mMTris and 192 mM glycine, pH 8.4, with and
without 1% deoxycholate in the cathode and anode chamber,
respectively. After transferred into nitrocellulose membrane, IRF3
monomers and dimers were detected by immunoblot using an
IRF3 anti-NES antibody (1:10, 000, IBL, Japan).
Immunoprecipitation assay
HEK293 cells (1610
6 cells/60-mm dish) were transiently
transfected with equal amounts (5 mg) of IRF3 and MYC-tagged
SOCS1 expression plasmids by using calcium phosphate precipita-
tion method. Cells were harvested 24 h post-transfection, washed
with 1 X phosphate-buffered saline (PBS), and lysed in a 1% Triton
X-100 lysis buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 1%
Triton X-100, 10% glycerol, 40 mM b-glycerophosphate, 0.1%
protease inhibitor cocktail, 1 mM phenylmethylsulfonyl fluoride,
1m MN a 3VO4, 5 mM NaF, 1 mM dithiothreitol). Immunoprecip-
itations were performed by incubating WCE (300 mg) with 1 mgo f
anti-MYC (9E10; Sigma-Aldrich, St. Louis, MO) or 1 mgo f
antiserum directed against IRF3 (rabbit polyclonal antibody, IBL,
Japan) coupled to 50 ml of A/G Plus-agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA) overnight at 4uC with constant
agitation. Immunocomplexes were washed at least 3 times in lysis
buffer eluted by boiling beads in 5 volumes SDS-PAGE sample
buffer. The proteins were fractioned on 10% SDS-PAGE,transferred
to nitrocellulose membrane and analyzed by immunoblot assay using
anti-MYC (Sigma-Aldrich) or anti-IRF3 (IBL, Japan) antibodies.
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Control and SOCS1-specific RNA interference sequences were
described previously [71,72]. SOCS1 protein was knocked down
using siSOCS (1), siSOCS (2) or a pool of the two siRNAs (siSOCS
(1) + siSOCS (2)). siRNAs were pulsed into MT-2 cells in a 0.4-cm
cuvette using a Gene Pulser II (Bio-Rad Laboratories) set at 0.25
kV and 0.95 mF. Cells were plated in six-well plates in complete
medium, washed 4 and 12 h later and collected at 72 h post-
transfection. RNA extinction efficiency was demonstrated by real
time PCR and immunoblot assay.
Statistical analysis
Data are presented as the mean 6 standard error of the mean
(SEM). Statistical significance for comparison of gene expression was
assessedbyanunpairedStudent’sttest,withtheexpectionofFigure4,
panels D and E where a two-way ANOVA with Bonferroni post-test
was used. Analyses were performed using Prism 5 software
(GraphPad). Statistical significance was evaluated using the following
p values: p,0.05 (*), p,0.01 (**) or p,0.001 (***).
Accession numbers
A list of accession numbers for genes and proteins mention in
this study are listed in Table S4.
Supporting Information
Figure S1 Confirmation of microarray results by Q-PCR. (A)
Total RNA of 9 donors (3 NI, 3 HAM, 3 ATL) was reverse
transcribed and cDNA was amplified using primers specific for
indicated genes by real-time PCR. Values were normalized to
GAPDH and relative quantification (RQ) was calculated by the
comparative CT method. (B) Raw data of array data (log2) and
real-time PCR data (log2RQ) for select genes. (C) Pearson
correlation data represent the strength and direction of the linear
relationship between real-time PCR assays and microarray data
represented in (B). Genes with a Pearson correlation value between
0.6 and 0.8 are represented in (C).
Found at: doi:10.1371/journal.ppat.1001177.s001 (0.95 MB TIF)
Figure S2 CEM and Jurkat CD4+ T cell lines express SOCS1
when treated with IFNa2b. Expression of SOCS1 was measured
in HTLV-1-negative T cell lines (CEM, Jurkat) with and without
1000U/ml of IFNa2b. cDNA was analyzed by quantitative real
time PCR to measured SOCS1 expression. Equivalent mRNA
amounts were normalized to GAPDH expression and calculated
as fold change with the levels of uninfected Jurkat cells set
arbitrarily as 1.
Found at: doi:10.1371/journal.ppat.1001177.s002 (0.44 MB TIF)
Figure S3 SOCS1 silencing in HTLV-1 infected MT-2 cells
restores endogenous IRF3 expression. MT-2 cells were electropo-
rated with control or pool of SOCS1 specific-siRNAs. At 72 h
post-transfection, cells lysates were prepared and equal amounts of
protein (20 mg) were resolved by SDS-PAGE followed by
immunoblotting with anti-SOCS1 or anti-IRF3 antibodies.
Immunoblotting against b-actin is shown as a loading control.
Found at: doi:10.1371/journal.ppat.1001177.s003 (0.55 MB TIF)
Table S1 Cohort #1 of HTLV-1 infected and non-infected
donors.
Found at: doi:10.1371/journal.ppat.1001177.s004 (0.07 MB
DOC)
Table S2 Cohort #2 of HAM/TSP and non-infected donors.
Found at: doi:10.1371/journal.ppat.1001177.s005 (0.04 MB
DOC)
Table S3 Supplemental material and methods for Q-PCR.
Found at: doi:10.1371/journal.ppat.1001177.s006 (0.03 MB
DOC)
Table S4 Accession numbers.
Found at: doi:10.1371/journal.ppat.1001177.s007 (0.04 MB XLS)
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